Kim KH, et al. - This study explored the risk factors for discontinuation of roflumilast in chronic obstructive pulmonary disease (COPD) patients. Compared with previous randomized controlled studies, higher rates of discontinuation and adverse events were reported in this study. Researchers found that discontinuation of roflumilast in ethnic Koreans was more likely in low-body mass index (BMI) patients. Moreover, low-BMI patients can more easily discontinue roflumilast in a clinical setting and hence clinicians are recommended to provide greater care for these patients.